Skip to main content
SpringerLink
Log in

Molecular Shuttle Chelation: The Use of Ascorbate, Desferrioxamine and Feralex-G in Combination to Remove Nuclear Bound Aluminum

  • Published:
Cellular and Molecular Neurobiology Aims and scope Submit manuscript

Abstract

1. Abundant data suggest that aluminum (Al(III)) exposure may be an environmental risk factor contributing to the development, progression and/or neuropathology of several human neurodegenerative disorders, including Alzheimer's disease (AD).

2. Nuclei appear to be one directed target for Al(III) binding, accumulation, and Al(III)-mediated dysfunction due in part to their high content of polyphosphorylated nucleic acids, nucleotides, and nucleoproteins.

3. The design of chelation therapies dealing with the removal of Al(III) from these genetic compartments therefore represents an attractive strategy to alleviate the development and/or progression of central nervous system dysfunction that may arise from excessive Al(III) exposure.

4. In this study we have investigated the potential application of 10 natural and synthetic Al(III) chelators, including ascorbate (AS), desferrioxamine (DF), and Feralex-G (FG), used either alone or in combination, to remove Al(III) preincubated with intact human brain cell nuclei.

5. Although nuclear bound Al(III) was found to be highly refractory to removal, the combination of AS+FG was found to be particularly effective in removing Al(III) from the nuclear matrix.

6. Our data suggest that chelators carrying cis-hydroxy ketone groups, such as FG, are particularly suited to the removal of Al(III) from complex biological systems.

7. We further suggest a mechanism whereby small chelating molecules may penetrate the nucleus, bind Al(III), diffuse to regions accessible by the larger DF or FG molecules and transfer their Al(III) to DF or FG.

8. The proposed mechanism, called molecular shuttle chelation may provide a useful pharmacotherapy in the potential treatment of Al(III) overload disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  • Allen, D. D., Orvig, C., and Yokel, R. A. (1994). Pharmacokinetics and distribution of tris(maltolato) aluminum (III) into the central nervous system. Neurotoxicology 15:371-378.

    Google Scholar 

  • Allen, T. D., Cronshaw, J. M., Bagley, S., Kiseleva, E., and Gordberg, M. W. (2000). The nuclear pore complex: Mediator of translocation between nucleus and cytoplasm. J. Cell Sci. 113:1651-1659.

    Google Scholar 

  • Andrade, J. P., Cadete-Leite, A., Paula-Barbosa, M. M., Volk, B., and Tavares, M. A. (1988). Long-term alcohol consumption reduces the number of neuronal nuclear pores. A morphometric study undertaken in CA3 hippocampal pyramids of rats. Alcohol. Clin. Exp. Res. 12:286-289.

    Google Scholar 

  • Blanusa, M., Prester, L., Varnai, V. M., Pavlovic, D., Kostial, K., Jones, M. M., and Singh, P. K. (2000). Chelation of aluminium by combining DF and L1 in rats. Toxicology 147:151-156.

    Google Scholar 

  • Bouras, C., Giannakopoulos, P., Good, P. F., Hsu, A., Hof, P. R., and Perl, D. P. (1987). A laser microscope mass analysis of brain aluminum and iron in dementia pugilistica: Comparison with Alzheimer's disease. Eur. J. Neurol. 38:53-58.

    Google Scholar 

  • Caravan, P., Rettig, S. J., and Orvig, C. (1997). Effect of pyridyl donors in the chelation of Al(III), gallium(III), and indium(III). Inorg. Chem. 36:1306-1315.

    Google Scholar 

  • Carpenter, D. O. (2001). Effects of metals on the nervous system of humans and animals. Int. J. Occup. Med. Environ. Health 14:209-218.

    Google Scholar 

  • Cherny, R. A., Barnham, K. J., Lynch, T., Volitakis, I., Li, Q. X., McLean, C. A., Multhaup, G., Beyreuther, K., Tanzi, R. E., Masters, C. L., and Bush, A. I. (2000). Chelation and intercalation: Complementary properties in a compound for the treatment of Alzheimer's disease. J. Struct. Biol. 130:209-216.

    Google Scholar 

  • CIBA-GEIGY Limited (1989). Technical Bulletin 992 810.5-957/2, CIBA-GEIGY Limited, Basel, Switzerland.

    Google Scholar 

  • Crapper, D. R., Quittkat, S., Krishnan, S. S., Dalton, A. J., and de Boni, U. (1980). UItranuclear aluminum content in Alzheimer's disease, dialysis encephalopathy and experimental aluminum encephalopathy. Acta Neuropathol. 50:19-24.

    Google Scholar 

  • Cuajungco, M. P., Faget, K. Y., Huang, X., Tanzi, R. E., and Bush, A. I. (2000). Metal chelation as a potential therapy for Alzheimer's disease. Ann. N.Y. Acad. Sci. 920:292-304.

    Google Scholar 

  • Exley, C. A. (1999). A molecular mechanism of aluminium-induced Alzheimer's disease. J. Inorg. Biochem. 76:133-140.

    Google Scholar 

  • Exley, C., and Korchazhkina, O. (2001). The association of Al and β-amyloid in Alzheimer's disease. In Exley, C. (ed.), Al and Alzheimer's Disease, The Science That Describes the Link, Elsevier, New York, pp. 421-433.

    Google Scholar 

  • Gelles, J., and Landick, R. (1998). RNA polymerase as a molecular motor. Cell 93:13-16.

    Google Scholar 

  • Hollosi, M., Shen, Z. M., Perczel, A., and Fasman, G. D. (1994). Stable intrachain and interchain complexes of neurofilament peptides: A putative link between Al3 and Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 91:4902-4906.

    Google Scholar 

  • Joshi, J. G. (1991). Neurochemical hypothesis: participation by Al in producing critical mass of colocalized errors in brain leads to neurological disease. Comp. Biochem. Physiol. 100:103-105.

    Google Scholar 

  • Kontoghiorghes, G. J. (1995). New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. Analyst 120:845-851.

    Google Scholar 

  • Kruck, T. P. A., and Burrow, T. E. (2002). Synthesis of Feralex-G: A novel aluminum/iron chelating compound. J. Inorg. Biochem. 88:19-24.

    Google Scholar 

  • Kruck, T. P. A., Krishnan, S. S., McLachlan, D. R. C., and Percy, M. E. (2002). Intramuscular injection of desferrioxamine lowers brain Al concentration in patients with Alzheimer's disease. In Khassanova, L., Collery, P. H., Maymard, I., Khassanova, Z., and Etienne, J. C. (eds.), Metal Ions in Biology and Medicine, Vol. 7, John Libbey Eurotext, Paris, pp. 189-192.

    Google Scholar 

  • Kruck, T. P. A., and McLachlan, D. R. (1989). Aluminum as a pathogenic factor in senile dementia of the Alzheimer type: Ion specific chelation. Prog. Clin. Biol. Res. 317:1155-1167.

    Google Scholar 

  • Lillie, R. D., Donaldson, P., Jirge, S. K., and Pizzolato, P. (1976). Iron and aluminum lakes of Gallo blue E as nuclear and metachromatic mucin stains. Stain Technol. 51:187-192.

    Google Scholar 

  • Lovell, M. A., Ehmann, W. D., and Markesbery, W. R. (1993). Laser microprobe analysis of brain aluminum in Alzheimer's disease. Ann. Neurol. 33:36-42.

    Google Scholar 

  • Lukiw, W. J. (1997). Aluminum in Alzheimer's Disease. In Yasui, M., Strong, M., Ota, K., and Verity, M. A. (eds.), Mineral and Metal Neurotoxicology, CRC Press, Boca Raton, FL, pp. 113-126.

    Google Scholar 

  • Lukiw, W. J. (2001). Al and gene transcription in the mammalian central nervous system. In Exley, C. (ed.), Al and Alzheimer's Disease, the Science That Describes the Link, Elsevier, New York, pp. 47-68.

    Google Scholar 

  • Lukiw, W. J., Bergeron, C., Wong, L., Kruck, T. P. A., Krishnan, B., and McLachlan, D. R. C. (1992). Nuclear compartmentalization of aluminum in Alzheimer's disease. Neurobiol. Aging 13:115-121.

    Google Scholar 

  • Lukiw, W. J., Kruck, T. P. A., and McLachlan, D. R. (1989). Aluminum, intracellular liganding and the nucleus. Lancet 1:781.

    Google Scholar 

  • Lukiw, W. J., LeBlanc, H. J., Carver, L. A., McLachlan, D. R., and Bazan, N. G. (1998). Run on transcription in human neocortical nuclei-inhibition by nanomolar aluminum and implications for neurodegenerative disease. J. Mol. Neurosci. 11:67-78.

    Google Scholar 

  • Lukiw, W. J., St. George-Hyslop, P., and McLachlan, D. R. C. (1994). Chromatin structure, nuclear aluminum and gene expression in Alzheimer's disease. In Basic and Clinical Aspects of Neuroscience, Regulation of Gene Expression and Brain Function, Sandoz Publications, Basel, Switzerland, pp. 31-45.

    Google Scholar 

  • Macdonald, T. L., and Martin, R. B. (1998). Aluminum ion in biological systems. Trends Biochem. Sci. 13:15-19.

    Google Scholar 

  • Martin, R. B. (1992). Aluminium speciation in biology. Ciba Found. Symp. 169:5-18.

    Google Scholar 

  • Murayama, H., Shin, R. R., Higuchi, J., Shibuya, S., Muramoto, T., and Kitamoto, T. (1999). Interaction of Al with PHF tau in Alzheimer's disease neurofibrillary degeneration evidenced by desferrioxamine-assisted chelating autoclave method. Am. J. Pathol. 155:877-885.

    Google Scholar 

  • Pante, N., and Kann, M. (2002). The nuclear pore complex is able to transport macromolecules with diameters of ∼39 nm. Mol. Biol. Cell 13:425-434.

    Google Scholar 

  • Perl, D. P. (2001). The association of Al and neurofibrillary degeneration in Alzheimer's disease, a personal perspective. In Exley, C. (ed.), Al and Alzheimer's Disease, the Science That Describes the Link, Elsevier, New York, pp. 133-146.

    Google Scholar 

  • Perl, D. P., Gajdusek, D. C., Garruto, R. M., Yanagihara, R. T., and Gibbs, C. J. (1982). Intraneuronal aluminum accumulation in amyotrophic lateral sclerosis and Parkinsonism-dementia of Guam. Science 217:1053-1055.

    Google Scholar 

  • Pratico, D., Uryu, K., Sung, S., Tang, S., Trojanowski, J. Q., and Lee, V. M.-Y. (2002). Aluminum modulates brain amyloidosis through oxidative stress in APP transgenic mice. FASEB J. 16:1138-1140.

    Google Scholar 

  • Rondeau, V., and Commenges, D. (2001). The epidemiology of Al and Alzheimer's disease. In Exley, C. (ed.), Al and Alzheimer's Disease, the Science That Describes the Link, Elsevier, New York, pp. 37-57.

    Google Scholar 

  • Shin, R.-W. (2001). Al, tau and neurofibrillary degeneration. In Exley, C. (ed.), Al and Alzheimer's Disease, the Science That Describes the Link, Elsevier, New York, pp. 411-420.

    Google Scholar 

  • Shin, R. W., Kruck, T. P. A., Murayama, H., and Kitamoto, K. (2003). A novel trivalent cation chelator Feralex-G dissociates binding of aluminum and iron associated with hyperphosphorylated tau of Alzheimer's disease. Brain Res. 961:139-46.

    Google Scholar 

  • Thompson, R. J. (1973). Studies on RNA synthesis in two populations of nuclei from the mammalian cerebral cortex. J. Neurochem. 21:19-40.

    Google Scholar 

  • Yokel, R. A. (1994). Al chelation: Chemistry, clinical, and experimental studies and the search for alternatives to desferrioxamine. J. Toxicol. Environ. Health 41:131-174.

    Google Scholar 

  • Yokel, R. A. (2002). Aluminum-chelation principles and recent advances. In Zatta, P. (ed.), Recent Topics in Aluminum Chemistry, Vol. 228: Coordination Chemistry Reviews, Elsevier, New York, pp. 97-113.

    Google Scholar 

  • Yokel, R. A., Ackrill, P., Burgess, E., Day, J. P., Domingo, J. L., Flaten, T. P., and Savory, J. (1996). Prevention and treatment of Al toxicity including chelation therapy: Status and research needs. J. Toxicol. Environ. Health 48:667-683.

    Google Scholar 

  • Yokel, R. A., Rhineheimer, S. S., Sharma, P., Elmore, D., and McNamara, P. J. (2001). Entry, half-life, and desferrioxamine-accelerated clearance of brain Al after a single (26)Al exposure. Toxicol. Sci. 64:77-82.

    Google Scholar 

  • Yoshida, S. (1991). Environmental factors in western Pacific foci of ALS and a possible pathogenetic role of aluminum (Al) in motor neuron degeneration. Rinsho Shinkeigaku 31:1310-1312.

    Google Scholar 

  • Yoshida, S., Mitani, K., Wakayama, I., Kihira, T., and Yase, Y. (1995). Bunina body formation in amyotrophic lateral sclerosis: A morphometric-statistical and trace element study featuring aluminum. J. Neurol. Sci. 130:88-94.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Surrey Place Centre and Department of Physiology, University of Toronto, Ontario, Canada

    Theo P. Kruck & Maire E. Percy

  2. Surrey Place Centre and Departments of Physiology and Obstretics and Gynecology, University of Toronto, Ontario, Canada

    Jian-Guo Cui & Walter J. Lukiw

Authors
  1. Theo P. Kruck
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jian-Guo Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maire E. Percy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Walter J. Lukiw
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kruck, T.P., Cui, JG., Percy, M.E. et al. Molecular Shuttle Chelation: The Use of Ascorbate, Desferrioxamine and Feralex-G in Combination to Remove Nuclear Bound Aluminum. Cell Mol Neurobiol 24, 443–459 (2004). https://doi.org/10.1023/B:CEMN.0000022773.70722.b2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:CEMN.0000022773.70722.b2

Search

Navigation